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Abstract
Background: Most malaria rapid diagnostic tests (RDTs) use HRP2 detection, including Paracheck-Pf®, but their
utility is limited by persistent false positivity after treatment. PLDH-based tests become negative more quickly, but
sensitivity has been reported below the recommended standard of 90%. A new pLDH test, CareStart™ three-line P.
f/PAN-pLDH, claims better sensitivity with continued rapid conversion to negative. The study aims were to 1)
compare sensitivity and specificity of CareStart™ to Paracheck-Pf® to diagnose falciparum malaria in children under
five years of age, 2) assess how quickly false-positive CareStart™ tests become negative and 3) evaluate ease of use
and inter-reader agreement of both tests.
Methods: Participants were included if they were aged between two and 59 months, presenting to a Médecins
Sans Frontières community health centre in eastern Sierra Leone with suspected malaria defined as fever (axillary
temperature > 37.5°C) and/or history of fever in the previous 72 hours and no signs of severe disease. The same
capillary blood was used for the RDTs and the blood slide, the latter used as the gold standard reference. All
positive participants were treated with supervised artesunate and amodiaquine treatment for three days.
Participants with a persistent false-positive CareStart™, but a negative blood slide on Day 2, were followed with
repeated CareStart™ and blood slide tests every seven days until CareStart™ became negative or a maximum of 28
days.
Results: Sensitivity of CareStart™ was 99.4% (CI 96.8-100.0, 168/169) and of Paracheck-Pf®, 98.8% (95% CI 95.8-99.8,
167/169). Specificity of CareStart™ was 96.0% (CI 91.9-98.4, 167/174) and of Paracheck-Pf®, 74.7% (CI 67.6-81.0, 130/
174) (p < 0.001). Neither test showed any change in sensitivity with decreasing parasitaemia. Of the 155 eligible
follow-up CareStart™ participants, 63.9% (99/155) had a false-positive test on day 2, 21.3% (33/155) on day 7, 5.8%
(9/155) on day 14, 1.9% (3/155) on day 21 and 0.6% (1/155) on day 28. The median time for test negativity was
seven days. CareStart™ was as easy to use and interpret as Paracheck-Pf® with excellent inter-reader agreement.
Conclusions: Both RDTs were highly sensitive, met WHO standards for the detection of falciparum malaria
monoinfections where parasitaemia was >100 parasites/μl and were easy to use. CareStart™ persistent false
positivity decreased quickly after successful anti-malarial treatment, making it a good choice for a RDT for a
hyperendemic falciparum malaria area.
* Correspondence: sgerstl@aol.com
1Médecins Sans Frontières (MSF UK), 67-74 Saffron Hill, London EC 1N 8QX,
UK
Gerstl et al. Malaria Journal 2010, 9:28
http://www.malariajournal.com/content/9/1/28
© 2010 Gerstl et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Prompt and accurate diagnosis followed by effective
treatment is currently the main malaria control strategy
besides preventive measures. Widespread documented
resistance to the older common anti-malarial mono-
therapies, notably chloroquine, has led to an increased
use of the highly effective artemisinin-based combina-
tion therapy (ACT) as the first-line treatment for
uncomplicated Plasmodium falciparum malaria [1,2].
Accurate confirmation of malaria diagnosis can reduce
the overuse of ACT treatment and, therefore, delay the
development of resistance. Moreover, it may both
reduce the risk of adverse drug reactions due to unne-
cessary treatment and increase correct treatment for
pathologies other than malaria. This, in turn, increases
patient and parents/caretakers confidence in health ser-
vices by providing accurate information for a proper
diagnosis [3,4]. Currently, the most commonly accepted
gold standard diagnostic method is microscopic reading
of a stained blood film. This requires laboratory techni-
cians with training and technical expertise, good quality
reagents, a well-maintained microscope and is time con-
s u m i n g .F r o me x p e r i e n c ei ti sc h a l l e n g i n gt oh a v e
microscopic results in less t h a nt w oh o u r s ,a sr e c o m -
mended by WHO, even with well-trained staff. In many
populations where malaria is prevalent, no laboratory
facilities and/or trained staff are present, making access
to microscopically confirmed diagnosis impossible. An
alternative to microscopy is to use a rapid diagnostic
test (RDT). Malaria RDT technology is attractive to
health care settings lacking in human resources espe-
cially facing a high caseload of patients with suspected
malaria, often including a high proportion of children
under five years of age. These tests can be used by per-
sonnel including laypersons, and not necessarily labora-
tory technicians, after limited training. Malaria RDT
results are on average available in less than 30 minutes.
The two types of RDT most often used belong to two
groups according to the detected antigens: those detect-
ing histidine-rich protein II (HRP2) and those detecting
parasite specific lactate dehydrogenase (pLDH).
HRP2 antigen is one of the three histidine-rich pro-
teins produced solely by trophozoites and young game-
tocytes of Plasmodium falciparum. RDTs based on the
detection of HRP2 can only diagnose Plasmodium falci-
parum infections and thus cannot be used for the detec-
tion of Plasmodium vivax or other human malarias
(Plasmodium ovale, Plasmodium malariae,a n dPlasmo-
dium knowlesi, the latter only recently be detected in
Asia [5]).
The malaria RDT most commonly used in the field
by Médecins Sans Frontières (MSF) at present is Para-
check-Pf®, which belongs to the HRP2 group.
Paracheck-Pf® has widely proven its field reliability to
detect Plasmodium falciparum in various continents,
countries and settings [i.e. [6-8]]. However, a limitation
of HRP2-based tests is their persistent false positivity
after effective treatment of the infection. HRP2 is only
slowly eliminated from the blood stream as it is
expressed in the erythrocyte membrane [9]. This fact
renders inconclusive a positive RDT result with a history
of a recently treated infection, especially in areas of high
transmission [i.e. [10-13]].
This is less of a problem with the pLDH- based tests.
PLDH is an intracellular metabolic enzyme produced by
all Plasmodium species that infect humans and is pro-
duced by sexual and asexual stages of the parasites.
PLDH is cleared more quickly from the bloodstream
than HRP2 after starting an effective treatment, as it is
an enzyme only produced by viable parasites [i. e.
[12,14-16]]. However, production of pLDH from game-
tocytes after elimination of asexual stages means some
tests will still stay falsely positive for several days [17].
As pLDH-based tests are able to detect all human
related Plasmodium, these RDTs could reduce the
chance of patients being treated unnecessarily for dis-
eases other than malaria or leave non-falciparum
malaria untreated as it would be the case with a HRP2-
based test.
Unfortunately, to date, the sensitivity of these tests,
under field conditions (mainly using the OptiMal-IT
test), has often been reported as lower than their HRP2
counterparts and falling below the internationally
recommended standard of 90% [8,18,19]. However, two
recent studies have shown more promising results with
sensitivities over 90% demonstrated with CareStart™
two-line PAN-pLDH and CareStart™ three-line P.f/PAN-
pLDH tests [12,20].
This study evaluated CareStart™ three-line P.f/PAN-
pLDH test in comparison to Paracheck-Pf®. CareStart™
three-line P.f/PAN-pLDH was chosen for three reasons.
First, CareStart™ three-line P.f/PAN-pLDH is able to
detect falciparum malaria as well as non-falciparum
malaria. In a region where falciparum malaria is predo-
minant but other species are also present, this test may
contribute to a more differentiated diagnosis of malaria.
Second, pLDH-based tests are cleared more rapidly
from the blood [12,14-16]. In regions with high malaria
transmission, it is especially important that RDTs can be
relied upon to test for new malaria infections shortly
after effective treatment of the initial diagnosis.
Third, among pLDH-based tests CareStart™ recently
showed its capacity to reach a sensitivity of over 90%
[12,20].
Paracheck-Pf® was chosen for comparison since it is
currently in use in the MSF project in Sierra Leone and
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falciparum [6-8,21]. Nevertheless, it has a relatively long
false positivity of the test after effective treatment of the
patient and only detects falciparum malaria [i.e. [11-21]].
There is an ongoing debate whether or not anti-malar-
ial treatment should be given to children under five
years of age only on the basis of clinical suspicion for
malaria [4,22-24]. There is a trend towards laboratory-
confirmed, usually RDT based, diagnosis [3,4]. However,
due to the lack of evidence, opinions vary broadly. So
far sensitivity and specificity studies for malaria RDTs,
with one exception in the Democratic Republic of
Congo [11], did not focus on children under five years
of age. Operational research is urgently needed to pro-
vide evidence for the use of malaria RDTs in this age
class.
The two main aims of the study were 1) to compare
the sensitivity and specificity of CareStart™ three-line P.
f/PAN-pLDH test and Paracheck-Pf® to diagnose Plas-
modium falciparum malaria in children under five years
of age using Giemsa-stained blood smears as gold stan-
dard reference and 2) to assess the time required for
false-positive CareStart™ three-line P.f/PAN-pLDH tests
to become negative after successful treatment with ACT.
Secondary aims included assessing ease of use and
inter-reader agreement of both malaria RDTs.
Methods
Study design
A prospective, single-blind evaluation of two RDTs
compared to slide microscopy.
Study site
The study was carried out in the Gerihun community
health centre (CHC) in Bo district, one of five CHCs in
which MSF is working. Bo district, situated in south-
east Sierra Leone, is a hyperendemic malaria region
where transmission is perennial. In 2008, of the 417,576
consultations in all MSF health facilities, 181,711
(43.5%) had uncomplicated malaria confirmed by RDT.
Severe malaria is the principal cause of morbidity in the
area, accounting in 2008 for 54.3% (3733/6875) of all
admissions of children under five years of age in the
paediatric department of the MSF-run referral hospital
(MSF, internal source, 2008/2009). For its catchment
population of 152,000 people MSF offers free malaria
diagnosis, treatment and prevention in a setting of free
primary heath care.
Enrolment of study participants
All children under five years of age consulting Gerihun
C H Cf o rf e v e ra n d / o rh i s t o r yo ff e v e ri nt h ep r e v i o u s
72 hours were screened for clinical suspicion of
malaria according to routine CHC protocols. Children
were included in the study if they satisfied all of the
following screening criteria: age between two and 59
months, suspected malaria defined as fever (axillary
temperature > 37.5°C), and/or history of fever in the
72 hours prior to attending Gerihun CHC, no signs of
severe disease and/or clinical danger, no treatment for
malaria administered within the previous four weeks,
and signed, informed consent by responsible
caregivers.
Patients were included for follow-up of the CareStart™
three-line P.f/PAN-pLDH test if they satisfied all of the
following criteria in addition to the initial inclusion cri-
teria: positive CareStart™ three-line P.f/PAN-pLDH test
for at least one malaria species and positive malaria
blood smear at Day 0 (day of inclusion), place of resi-
dence less than one hour walking distance from Gerihun
CHC, and able to attend follow-up for up to 28 days.
Sample size
To detect Plasmodium falciparum with a sensitivity of
90%, 138 blood smear positive patients were required
(alpha error 0.05, precision 5%). Similar calculations
applied to the specificity, so an additional 138 blood
smear negative patients needed to be tested. To allow
for an estimated 5% of patients with incomplete infor-
mation, patients were continuously recruited until a
minimum of 145 positive and 145 negative blood smears
had been included. The study was not powered to evalu-
ate detection of malaria species other than Plasmodium
falciparum, or mixed infections that included Plasmo-
dium falciparum.
A convenient sample size of 145 patients with a posi-
tive CareStart™ three-line P.f/PAN-pLDH test result and
positive malaria blood smear at Day 0 (day of inclusion)
was chosen to describe the time taken for the false-posi-
tive CareStart™ three-line P.f/PAN-pLDH tests to
become negative.
Study procedures
On the day of inclusion, demographic and clinical
information were recorded, thick and thin blood
smears prepared, and the two malaria RDTs (CareS-
tart™ three-line P.f/PAN-pLDH test and Paracheck-Pf®)
performed. Treatment was based on the results of the
blood smear, taken as the gold standard reference
diagnosis. All positive patients were treated for free
according to the following treatment scheme recom-
mended by World Health Organization (WHO), the
national and MSF protocol: artesunate 4 mg/kg body
weight and amodiaquine 10 mg/kg body weight once a
day on Days 0-2. Patients eligible for the follow-up
part of the study had all been treated with three doses
of artesunate and amodiaquine, administered at the
study site, and were observed over the first 30 minutes
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course of treatment at the study site resulted in exclu-
sion from the follow-up study part.
Follow-up of CareStart™ three-line P.f/PAN-pLDH false-
positive tests
Patients with a positive CareStart™ three-line P.f/PAN-
pLDH test and a negative blood smear on the last day
of treatment, Day 2, were followed from Day 2 with
repeated CareStart™ three-line P.f/PAN-pLDH tests
and blood smears at 7-day intervals until the CareS-
tart™ three-line P.f/PAN-pLDH test results were nega-
tive or a maximum of 28 study inclusion days were
reached.
Evaluation of malaria rapid diagnostic tests (RDTs)
Both malaria RDTs were of traceable quality (standard
supplier, used within the shelf life) and had a guaranteed
history of proper storage and transport conditions. All
RDTs were performed and interpreted according to the
manufacturers’ instructions.
1) CareStart™ three-line P.f/PAN-pLDH (batch num-
ber AI8IL, manufacturer’s catalogue number G0121,
AccessBio, New Jersey, USA) is an individually packaged
test cassette, diagnosing Plasmodium infections by
pLDH detection, distinguishing between Plasmodium
falciparum and the other malaria species Plasmodium
vivax, Plasmodium malariae,o rPlasmodium ovale.I t
requires 5 μlo fw h o l eb l o o dt ob ec o l l e c t e dw i t hap i p -
ette provided by the test kit. Test results need to be
read after 20 minutes.
2) Paracheck-Pf® (batch numbers 31930 and 31932,
manufacturer’s catalogue number 30301025, Orchid Bio-
medical System, Goa, India) is also an individually pack-
aged test cassette, diagnosing Plasmodium falciparum
infections by HRP2 detection. It requires 5 μlo fw h o l e
blood to be collected with a sample applicator provided
by the test kit. Test results need to be read after 15
minutes.
Test results were read by two independent readers,
who received training before the beginning of the
study. The readers were taught the procedure and
interpretation of the RDT results. The study did not
start until the study supervisor was satisfied that the
readers were familiar with handling and reading of
both tests. Preparation and reading of the RDTs were
continually reviewed under the observation of the
study supervisor. The first reading was performed at
the time specified by the manufacturer. The person
doing the first reading was a trained laboratory techni-
cian and also prepared the two RDTs beforehand. As
the two manufacturers provided no maximum time
before reading the results, the second reading was per-
formed less than 10 minutes after the first. The second
reading was done by a trained layperson. The readers
were blinded to each other’s results and to that of the
blood smear. For each RDT the result was classified as
negative, positive (differentiating for the CareStart™
three-line P.f/PAN-pLDH test Plasmodium falciparum
or other Plasmodium species) or invalid. All tests with-
out a control line were considered invalid by the first
reader and were repeated.
Laboratory procedures
Thick and thin blood smears and RDTs were performed
from the same finger-prick of blood. Thick and thin
smears were prepared on the same slide and were air-
dried. The thin blood smears were fixed with methanol
and the thick smears left unfixed. Each slide was then
stained with 10% Giemsa solution for ten minutes. All
blood smears were examined microscopically under oil
immersion (× 1,000 magnification). The thick smears
were used for diagnosis of Plasmodium species and for
parasite-density counting. Smears were considered nega-
tive if no parasites were seen in 100 oil-immersion
fields. For positive smears, the number of parasites was
counted against 200 white blood cells (WBC), or 500
WBC for low-density infections. Parasite density was
calculated assuming 8,000 WBC per microlitre. The thin
smears were examined to confirm the parasite species
for positive samples. Gametocyte presence or absence
on all slides was also recorded, and species identification
and gametocyte-density counts (number of gametocytes/
1,000 WBC) performed.
All inclusion slides were double-read, blinded, by
experienced technicians (one in the MSF project in
Sierra Leone and one in MSF Austria that has staff with
a special focus on laboratory quality). A third reading
was performed in case of discordance, such as positive/
negative discordance for asexual stages, species discor-
dance for asexual stages, asexual density discordance
(difference in parasitaemia ≥50%), and/or positive/nega-
tive gametocyte discordance. Third readings were per-
formed by the Department of Infectious and Tropical
Diseases at the London School of Hygiene and Tropical
Medicine and were taken as the definitive results for
these slides being disconcordant between the first and
the second reader.
Assessment of ease of use of RDTs
At the end of the field part of the study, the ease of
use of both RDTs was compared using quantitative
(storing conditions) and qualitative criteria. The study
laboratory technicians who performed the RDTs were
asked to rank the tests independently in order of pre-
ference where “2” corresponded to their most preferred
test and “0” to their least preferred in each of the fol-
lowing categories: Ease and safety of taking blood, ease
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instructions. The trained laypersons who were per-
forming second readings of tests were asked to rank
the tests independently based on the ease of interpre-
tation, and for any additional comments where “2” cor-
responded to their most preferred test and “0” to their
least preferred.
Data management and analysis
All data were recorded directly on an individually num-
bered case report form. Data were entered into EpiData
3.0 software (The EpiData Association, Odense, Denmark).
Data cleaning was done to check for inconsistencies in
data entry and responses. Data analysis was conducted
using Stata 8.0 (Stata Corporation, College Station, Texas,
USA) and SPSS 11.0 (SPSS. Chicago, USA).
Baseline characteristics (demographic, clinical, and
parasitological) were analysed using descriptive statistics
(means, inter-quartile ranges and values). Sensitivity was
defined as the proportion of true malaria cases (positive
blood smears) that were correctly identified by positive
RDTs. Specificity was the proportion of true negative
malaria cases (negative blood smears) that were cor-
rectly identified by negative RDTs. Positive predictive
value was the proportion of true malaria cases (positive
blood smears) among the total number of positive
RDTs. Negative predictive value was the proportion of
true negative malaria cases (negative blood smears)
among the total number of negative tests.
Sensitivity, specificity, positive and negative predictive
values of each test were calculated for RDTs performed
at the day of inclusion and estimated using microscopy
as the reference standard. Sensitivity, specificity, positive
and negative predictive values were also stratified by
category of parasitaemia (<100, <1,000, ≥1,000 parasites/
μl). The first reading of the RDTs was used for these
calculations. A 95% confidence interval (95% CI) was
given for each parameter. Proportions (paired data) were
compared using the McNemar test. Agreement between
readers of each RDT was assessed using the kappa coef-
ficient. A Kappa coefficient greater than 0.8 was consid-
ered as a measure of good agreement.
Ethical issues
Approval was received from the Ethics Review Board of
MSF and the Research and Ethics Committee of the
Ministry of Health and Sanitation of Sierra Leone.
Informed, written consent was sought from responsible
caregivers of all children participating in the study. The
caregivers were provided with an information sheet and
had the study purpose explain e di nt h e i ro w nl a n g u a g e
by the study personnel (Mende, Creole or English). Par-
ticipation was entirely voluntary.
Results
Demographic and parasitological characteristics of study
patients
Between 17 March and 15 July, 2008, 343 participants
under five years of age were included in the study. Base-
line characteristics of the study population are shown
in Table 1. None of the children’s caregivers refused
to participate in the study. Among the 343 study
Table 1 Baseline characteristics of all study patients and parasitological characteristics of slide-positive participants
attending Gerihun community health centre in Bo district, Sierra Leone, Africa, 2008
Baseline characteristics (N = 343)
Age:
Mean, median in months (IQR
#) 23,20 (9-36)
Range in months (Minimum, Maximum) 2,58
2 - 23 months (%) 252 (73.4%)
24 - 59 months (%) 91 (26.6%)
Gender ratio (male/female) 1.1 (177/166)
Median weight in kg (IQR
#) 9.5 (7.8-11.8)
Median temperature on day 0 (IQR
#) 37.8 (37.6-38.4)
Temperature > 37.5° C on day 0 (%, n/N) 75.2 (258/343)
Parasitological characteristics (N = 169)
Asexual parasitaemia density range (parasites/μl) 1 - 2136000
Median of asexual parasitaemia density (parasites/μl) 264000
Inter-quartile parasitaemia density range (parasites/μl) 2620-79921
Gametocyte carriage for Plasmodium falciparum (n, %) 17, 10.1%
Median number of gametocyte density
† (IQR
#) 3 (2-13)
# IQR: inter-quartile range
† Number of gametocytes per 1000 white blood cells
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tart™ three-line P.f/PAN-pLDH false-positive tests at
Day 0 (day of inclusion). Of the 176 study participants
not eligible for follow-up at Day 0 (day of inclusion),
167 had a CareStart™ three-line P.f/PAN-pLDH negative
test in combination with a negative blood smear, seven
had a CareStart™ three-line P.f/PAN-pLDH false-positive
test in combination with a negative blood smear, and
two failed to complete the full course of anti-malarial
treatment under supervision. Of the 343 patients tested
at Day 0 of the study, 46.7% (169/343) had malaria posi-
tive blood smears. The only species detected in the posi-
tive blood smears was Plasmodium falciparum.
Parasitological characteristics of smear-positive study
participants are given in Table 1. A high parasitaemia,
defined as ≥ 1,000 parasites/μl, was seen in 82.8% (140/
169) of the study patients. Of these, 49.3% (69/140) had
≥ 50,000 parasites/μl. Seventeen study patients had a
positive blood smear with both asexual stages and game-
tocytes (10.1%).
Accuracy of RDTs
There was no significant difference between the sensitiv-
ity of CareStart™ three-line P.f/PAN-pLDH (168/169,
99.4%) and Paracheck-Pf® (167/169, 98.8%) (Table 2).
CareStart™ three-line P.f/PAN-pLDH was significantly
more specific than Paracheck-Pf® with 96.0% (167/174)
and 74.7% (130/174), respectively (p < 0.001). Stratifica-
tion by level of parasitaemia (<100 versus ≥100 para-
sites/μl and <1,000 versus ≥1,000 parasites/μl) did not
show any differences in terms of sensitivity and specifi-
city results of the two RDTs. The only false negative
result for CareStart™ three-line P.f/PAN-pLDH test had
a parasitaemia of 1-2 parasites/μl .T h et w os t u d yp e r -
sons with false negative results for Paracheck-Pf® test
had a parasitaemia of 288,000 and 580,000 parasites/μl.
Follow-up of false-positive CareStart™ three-line P.f/PAN-
pLDH test after successful anti-malarial treatment
Out of the 167 study patients eligible for follow-up, 12
were lost to analysis. Five defaulted at Day 1, one had
an incorrect artesunate and amodiaquine intake on Day
2, one needed referral to the hospital due to deteriorat-
ing health status, and five blood slides from Day 2 were
broken during transport and consequently were unread-
able. Altogether, 155 study patients were included in the
follow-up analysis. There were no positive blood smears
for any of the 155 study patients on any of the follow-
up days. A positive CareStart™ 3 line P.f/PAN-pLDH
test during that period was considered as a false-positive
result.
On Day 2 of follow-up, 63.9% (95% CI 56.0-71.0, 99/
155) of the study participants had a CareStart™ three-
line P.f/PAN-pLDH false-positive test. Similarly, on day
seven, 21.3% (95% CI 15.6-28.4, 33/155), on day 14,
5.8% (95% CI 3.0-10.7, 9/155), on day 21, 1.9% (95% CI
0.6-5.5, 3/155) and on day 28, 0.6% (95% CI 0.1-3.6, 1/
155) had false-positive tests (Figure 1). The median time
for CareStart™ three-line P.f/PAN-pLDH test to become
negative during the follow-up was seven days (mean 7
days, inter-quartile range 2-7 days).
Ease of use and reliability of RDTs
Remarks made were that the two RDTs were equally
safe for personnel to handle and easy to use in terms of
adding blood and reagents. Both the control and the
positive test lines were equally readable in both RDTs.
The instruction sheet provided with Paracheck-Pf®
included more detailed and comprehensive information
than that provided with the CareStart™ three-line P.f/
PAN-pLDH test. This was true for both general back-
ground information and specific practical information
about the test and its component parts. For example,
Table 2 Accuracy of CareStart™ three-line P.f/PAN-pLDH and Paracheck-Pf® malaria rapid diagnostic tests for the
detection of Plasmodium falciparum in patients attending Gerihun community health centre in Bo district, Sierra
Leone, Africa, 2008
CareStart™ 3 line P.f/PAN-pLDH Paracheck-Pf®
Sensitivity % (95% CI
#) 99.4 (96.8 - 100.0) 98.8 (95.8 - 99.8)
n/N 168/169 167/169
Specificity
Ψ % (95% CI
#) 96.0 (91.9 - 98.4) 74.7 (67.6 - 81.0)
n/N 167/174 130/174
PPV
† % (95% CI
#) 96.0 (91.9 - 98.4) 79.2 (73.0 - 84.4)
n/N 168/175 167/211
NPV
‡ % (95% CI
#) 99.4 (96.7 - 100.0) 98.5 (94.6 - 99.8)
n/N 167/168 130/132
Kappa coefficient % (95% CI
#) 0.95 (0.92 - 0.98) 0.99 (0.98 - 1.0)
# Confidence interval
Ψ p<0 . 0 0 1
† Positive predictive value
‡ Negative predictive value
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the presence of the packet of silica gel and that a colour
change in this gel from blue to pink signified that the
test had been exposed to compromising levels of humid-
ity which invalidate the test. The CareStart™ three-line
P.f/PAN-pLDH tests were packed with a small tablet,
which had no identification markings. There was no
information about this tablet in the instruction sheet
provided. Both tests were simple to store with no cold
chain requirement for either test. In terms of storage
capacity, one box of 75 CareStart™ three-line P.f/PAN-
pLDH tests was approximately the same size as one box
of 25 Paracheck-Pf® tests. However, the CareStart™
three-line P.f/PAN-pLDH box did not include lancets or
alcohol swabs. Both tests had equal scores in ranking.
The number of invalid tests was 0.6% (4/605) for CareS-
tart™ three-line P.f/PAN-pLDH and 0.3% (1/343) for
Paracheck-Pf®.
The control and the positive test lines were equally
readable for both RDTs. Kappa coefficient for the inter-
reader reliability for both RDTs tests was above 0.9
(Table 2).
Discussion
Both malaria RDTs, CareStart™ three-line P.f/PAN-
pLDH and Paracheck-Pf®, were highly sensitive for the
detection of falciparum malaria monoinfections in chil-
dren under five years of age. When a parasitaemia of
more than 100 parasites per microlitre was considered,
both tests were >95% sensitive for the detection of
Plasmodium falciparum, meeting the criteria set out by
WHO [19,25]. A literature search produced only two
other published studies assessing the sensitivity of Car-
eStart™ RDTs to detect Plasmodium falciparum malaria
in Africa. Both studies used the two-line test and did
not exclusively focus on children under five years of age.
They included a field study in Uganda, which found sen-
sitivity of the CareStart™ two-line PAN-pLDH test to be
95.6% [12], and a study in Madagascar, where sensitivity
of CareStart™ two-line PAN-pLDH was 97% [20]. In a
survey carried out recently in Myanmar, CareStart™
three-line P.f/PAN-pLDH tests had a sensitivity of 94.7%
[26]. The results of these studies confirm the high sensi-
tivity of CareStart™ tests and make this pLDH-based test
a strong candidate for consideration when selecting the
most suitable RDT in projects in hyperendemic falci-
parum malaria areas.
Both malaria RDTs were very reliable, having less than
one percent invalid tests. Inter-reader reliability was
equally good, indicating that wherever the tests are
used, readers will be able to give trustworthy results.
Both tests were perceived by the study team as similar
in terms of ease of use. Therefore, neither RDT was pre-
ferable based on these characteristics.
Heat-stability has been a major concern for pLDH
tests, especially under field conditions [27]. Due to very
basic field conditions no stability testing was carried out
in this study. However in a study carried out in Myan-
mar CareStart™ three-line P.f/PAN-pLDH tests remained
stable for up to 90 days at 35°C [26]. In the 2009
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Figure 1 Proportion of false-positive CareStart™ three-line P.f/PAN-pLDH tests on each follow-up visit of study patients attending
Gerihun community health centre in Bo district, Sierra Leone, Africa, 2008.
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lity of CareStart™ two-line PAN-pLDH remained stable
for up to 60 days at 4°C, 35°C and 45°C [28]. Thus, sta-
bility of the CareStart™ three-line P.f/PAN-pLDH seems
to be satisfactory.
The major advantage of pLDH-based tests over HRP2-
based tests is their ability to rapidly become negative
after effective treatment with an anti-malarial. This is in
contrast to Paracheck-Pf® that remains false-positive for
up to four weeks after successful treatment. In the
Democratic Republic of Congo, 73.5% of effectively trea-
ted children were still Paracheck-Pf® false-positive at
Day 35 [11]. In Uganda, 69.7% of successfully treated
patients remained Paracheck-Pf® false-positive at Day 14
[12]. In southern Vietnam, the Paracheck-Pf® false posi-
tivity rate was around 30% at Day 28 of follow-up [21].
The first results seen with CareStart™ were very promis-
ing - in Uganda 14 days after treatment only 10% of the
CareStart™ 2 line PAN-pLDH tests remained false-posi-
tive. In that study, the follow-up stopped at Day 14 [12].
This rapid return to negativity was further confirmed in
the present study. CareStart™ 3 line P.f/PAN-pLDH
became negative after a median of seven days. On the
14
th day of follow-up less than 6% of the study patients
still tested false-positive, approximately half the percen-
tage found false-positive during the Uganda study at the
same follow-up day. At Day 28, less than one percent of
the study patients were still false-positive. Especially in a
hyperendemic setting, it is extremely important to have
a short parasite antigen clearance time after parasites
are removed. This characteristic allows health personnel
to confidently interpret positive RDT results without
concerns over possible false-positive results from pre-
viously treated infections.
At the time this study was planned (early 2008),
WHO did not endorse any particular RDT, but listed
products submitted to the WHO malaria RDT product
testing programme [29]. By April 2009, the outcome of
the first round of product testing malaria antigen-
detecting RDTs was made public [28]. Both of the
RDTs test manufacturers in this study were invited to
submit up to three tests for evaluation. AccessBio sub-
mitted the CareStart™ two-line PAN-pLDH test while
Orchid Biomedical System participated with Para-
check-Pf®. All tests were evaluated using prepared
blood panels of cultured Plasmodium falciparum para-
sites and patient-derived Plasmodium falciparum and
Plasmodium vivax parasites, and a parasite-negative
panel.
In the WHO evaluation, CareStart™ two-line PAN-
pLDH performed better than Paracheck-Pf® in terms of
detection rate of parasites, inter-reader agreement, and
heat stability. However, they both showed an equivalent
high level of detection at a high parasite density (2,000
or 5,000 parasites/μL). It has to be noted that the WHO
testing was an evaluation of the performance under
laboratory conditions. In contrast, this study was carried
o u ti nt h ef i e l da n dw a st h ef i r s tt od os of o c u s i n go n
children under five years of age under these conditions.
Future procurement decisions should be based on
WHO test results, but need to take into consideration
local conditions of malaria transmission and illness
where the test will be used. Nevertheless, to centralise
RDT product testing in vitro is a very welcome initiative
from WHO to facilitate the evaluation of reliable RDTs
in the field.
There are some potential limitations in generalizing
this promising CareStart™ three-line P.f/PAN-pLDH test
as a suitable candidate for malaria diagnosis. The study
team was well-trained and constantly supervised in test
preparation and interpretation. This might not be the
case in all health facilities using this technology. Also,
the study cohort only had Plasmodium falciparum
malaria species to detect. CareStart™ three-line P.f/PAN-
pLDH tests might perform less satisfactorily in settings
where other malaria species predominate, which was the
case in a study in Myanmar [26]. As the study partici-
pants all had a mono-infection with Plasmodium falci-
parum no conclusions can be drawn in terms of
sensitivity of CareStart™ three-line P.f/PAN-pLDH test
for the other Plasmodium infections. This confirms the
need to carry out RDT assessments in different geogra-
phical areas and with different types and levels of trans-
mission in order to find the most suitable test for each
region.
Several studies demonstrate inconsistencies in blood
smear reading and, therefore, possibly doubtful results
for sensitivity and specificity of malaria RDTs [30,31].
Some studies even suggest that RDTs perform better
than microscopy under routine conditions [32] or at
parasite densities below the threshold for detection by
microscopy [33]. Because blood smears were used as the
gold standard reference to compare both RDTs under
evaluation, extra emphasis was placed on quality control
of the blood smears. All slides were read twice, by two
independent well-trained microscopists, who were
blinded to both the RDTs results and the findings of
their counterpart. In addition, all slides with disconcor-
dant results were read a third time by the Department
of Infectious and Tropical Diseases at the London
School of Hygiene and Tropical Medicine in London.
Conclusions
Before choosing a malaria RDT for use in the field it
must fulfil a number of requirements. In this study Car-
eStart™ three-line P.f/PAN-pLDH fulfilled all the
requested criteria: (1) Sensitivity for the diagnosis of fal-
ciparum malaria was more than 95% with a parasitaemia
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(specificity, positive and negative predictive values) were
above 90%. (3) The test had an excellent inter-reader
agreement and was reliable, easy to use and interpret.
(4) False positivity decreased rapidly after successful
anti-malarial treatment and became, on average, nega-
tive after seven days.
This study confirms the value of RDTs for use in
children under five years of age by refuting the idea
that RDTs may miss a significant number of diagnoses
in this age group. Widespread use of RDTs should
improve diagnostic accuracy of malaria in the field and
should be adopted by malaria control programmes.
These results confirm that, in terms of accuracy, Car-
eStart™ three-line P.f/PAN-pLDH test can be used as
an alternative to Paracheck-Pf® in hyperendemic set-
tings where Plasmodium falciparum malaria is the pre-
dominant species.
On the basis of this study, policy makers and govern-
mental and non-governmental health providers can con-
sider CareStart™ three-line P.f/PAN-pLDH test as a
valuable tool for diagnosing falciparum malaria in chil-
dren under five years of age, especially in more remote
areas with hyperendemic conditions. This supports the
wider use of RDTs to accurately diagnose malaria and
avoid over or under treatment.
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